IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas

Brunangelo Falini, Claudio Agostinelli, Barbara Bigerna, Alessandra Pucciarini, Roberta Pacini, Alessia Tabarrini, Flavio Falcinelli, Milena Piccioli, Marco Paulli, Marcello Gambacorta, Maurilio Ponzoni, Enrico Tiacci, Stefano Ascani, Maria Paola Martelli, Riccardo Dalla Favera, Harald Stein, Stefano A. Pileri

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.

Original languageEnglish
Pages (from-to)930-941
Number of pages12
JournalHistopathology
Volume61
Issue number5
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Immunoglobulins
Lymphoma
B-Lymphocytes
Lymphoid Tissue
Germinal Center
B-Cell Lymphoma
Plasma Cells
Mucous Membrane
Spleen
Epithelium
Lymph Nodes
Monoclonal Antibodies
Phenotype
Growth

Keywords

  • Immunohistochemistry
  • IRTA1
  • Marginal zone lymphomas
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Falini, B., Agostinelli, C., Bigerna, B., Pucciarini, A., Pacini, R., Tabarrini, A., ... Pileri, S. A. (2012). IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology, 61(5), 930-941. https://doi.org/10.1111/j.1365-2559.2012.04289.x

IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. / Falini, Brunangelo; Agostinelli, Claudio; Bigerna, Barbara; Pucciarini, Alessandra; Pacini, Roberta; Tabarrini, Alessia; Falcinelli, Flavio; Piccioli, Milena; Paulli, Marco; Gambacorta, Marcello; Ponzoni, Maurilio; Tiacci, Enrico; Ascani, Stefano; Martelli, Maria Paola; Favera, Riccardo Dalla; Stein, Harald; Pileri, Stefano A.

In: Histopathology, Vol. 61, No. 5, 11.2012, p. 930-941.

Research output: Contribution to journalArticle

Falini, B, Agostinelli, C, Bigerna, B, Pucciarini, A, Pacini, R, Tabarrini, A, Falcinelli, F, Piccioli, M, Paulli, M, Gambacorta, M, Ponzoni, M, Tiacci, E, Ascani, S, Martelli, MP, Favera, RD, Stein, H & Pileri, SA 2012, 'IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas', Histopathology, vol. 61, no. 5, pp. 930-941. https://doi.org/10.1111/j.1365-2559.2012.04289.x
Falini B, Agostinelli C, Bigerna B, Pucciarini A, Pacini R, Tabarrini A et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012 Nov;61(5):930-941. https://doi.org/10.1111/j.1365-2559.2012.04289.x
Falini, Brunangelo ; Agostinelli, Claudio ; Bigerna, Barbara ; Pucciarini, Alessandra ; Pacini, Roberta ; Tabarrini, Alessia ; Falcinelli, Flavio ; Piccioli, Milena ; Paulli, Marco ; Gambacorta, Marcello ; Ponzoni, Maurilio ; Tiacci, Enrico ; Ascani, Stefano ; Martelli, Maria Paola ; Favera, Riccardo Dalla ; Stein, Harald ; Pileri, Stefano A. / IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. In: Histopathology. 2012 ; Vol. 61, No. 5. pp. 930-941.
@article{04278b1e657b443585cd0780107536c8,
title = "IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas",
abstract = "Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93{\%}) and nodal MZLs (73{\%}) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.",
keywords = "Immunohistochemistry, IRTA1, Marginal zone lymphomas, Monoclonal antibodies",
author = "Brunangelo Falini and Claudio Agostinelli and Barbara Bigerna and Alessandra Pucciarini and Roberta Pacini and Alessia Tabarrini and Flavio Falcinelli and Milena Piccioli and Marco Paulli and Marcello Gambacorta and Maurilio Ponzoni and Enrico Tiacci and Stefano Ascani and Martelli, {Maria Paola} and Favera, {Riccardo Dalla} and Harald Stein and Pileri, {Stefano A.}",
year = "2012",
month = "11",
doi = "10.1111/j.1365-2559.2012.04289.x",
language = "English",
volume = "61",
pages = "930--941",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas

AU - Falini, Brunangelo

AU - Agostinelli, Claudio

AU - Bigerna, Barbara

AU - Pucciarini, Alessandra

AU - Pacini, Roberta

AU - Tabarrini, Alessia

AU - Falcinelli, Flavio

AU - Piccioli, Milena

AU - Paulli, Marco

AU - Gambacorta, Marcello

AU - Ponzoni, Maurilio

AU - Tiacci, Enrico

AU - Ascani, Stefano

AU - Martelli, Maria Paola

AU - Favera, Riccardo Dalla

AU - Stein, Harald

AU - Pileri, Stefano A.

PY - 2012/11

Y1 - 2012/11

N2 - Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.

AB - Aims: The aim of this study was to search for a molecule selectively expressed by marginal zone (MZ) lymphomas (MZLs), whose diagnosis is currently based on morphological criteria and negativity for markers detectable in other B-cell lymphomas. Methods and results: Two thousand one hundred and four peripheral lymphomas of various types were immunostained with a monoclonal antibody against immunoglobulin superfamily receptor translocation-associated 1 (IRTA1), which recognizes the equivalents of MZ in human lymphoid tissues other than spleen. IRTA1 expression was restricted to extranodal (93%) and nodal MZLs (73%) and to lymphomas with MZ differentiation. Extranodal MZL cells with the strongest IRTA1 expression were usually located adjacent to epithelia, mimicking the IRTA1 expression pattern of normal and acquired mucosa-associated lymphoid tissue (MALT). The cytological features, growth pattern and IRTA1 positivity in nodal MZLs suggest they may derive from IRTA1+ perifollicular B cells or monocytoid B cells detectable in reactive lymph nodes. Double immunostaining for IRTA1/bcl-6 tracked the colonization of B-cell follicles by MZL cells, and showed modulation of their phenotype (e.g. acquisition of bcl-6) during recirculation through germinal centres. MZL cells differentiating into plasma cells usually lost IRTA1. Conclusions: These results further expand our knowledge of the biology of MZLs, and highlight IRTA1 as the first positive marker for MZLs, enabling more accurate diagnosis of these neoplasms.

KW - Immunohistochemistry

KW - IRTA1

KW - Marginal zone lymphomas

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84868136434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868136434&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2012.04289.x

DO - 10.1111/j.1365-2559.2012.04289.x

M3 - Article

C2 - 22716304

AN - SCOPUS:84868136434

VL - 61

SP - 930

EP - 941

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 5

ER -